OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 199,072 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 199,072 shares of OPKO Health stock in a transaction that occurred on Friday, November 29th. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $304,580.16. Following the purchase, the chief executive officer now owns 211,911,477 shares of the company’s stock, valued at $324,224,559.81. The trade was a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Trading Down 2.5 %

Shares of OPKO Health stock traded down $0.04 during midday trading on Friday, reaching $1.54. 2,936,770 shares of the company’s stock traded hands, compared to its average volume of 6,884,610. The company has a market cap of $1.05 billion, a PE ratio of -8.32 and a beta of 1.65. The stock has a 50 day moving average of $1.51 and a 200-day moving average of $1.45. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP increased its position in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. raised its stake in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after buying an additional 876,272 shares in the last quarter. Y.D. More Investments Ltd bought a new position in OPKO Health in the second quarter worth about $1,840,000. PFG Investments LLC raised its stake in OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after buying an additional 100,125 shares in the last quarter. Finally, Clearline Capital LP bought a new position in OPKO Health in the third quarter worth about $1,083,000. 64.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on OPK. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.